Pharmaceutical composition for treating atherosclerosis and application

A technology of atherosclerosis and composition, applied in the field of medicine, can solve problems such as unsatisfactory effects, achieve obvious damage to arterial endothelial cells, obvious effect, and the effect of treating arterial endothelial cell damage

Inactive Publication Date: 2017-01-04
XINXIANG MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

General prevention is mainly based on reasonable diet, physical exercise, and attention to rest, but the effect is not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating atherosclerosis and application
  • Pharmaceutical composition for treating atherosclerosis and application
  • Pharmaceutical composition for treating atherosclerosis and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] A pharmaceutical composition for treating atherosclerosis. The pharmaceutical composition is prepared from the following raw materials: 101 parts of Cyclovir buxicine D, 6 parts of glucoside and 9 parts of swertiamarin.

Embodiment 2

[0036] A pharmaceutical composition for treating atherosclerosis. The pharmaceutical composition is prepared from the following raw materials: 0.5 parts of cyclovir buxicine D, 105 parts of glucoside, and 102 parts of swertiamarin.

Embodiment 3

[0038] A pharmaceutical composition for treating atherosclerosis. The pharmaceutical composition is prepared from the following raw materials: 103 parts of cyclovir buxicine D, 7 parts of glucoside and 103 parts of swertiamarin.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to a pharmaceutical composition for treating atherosclerosis and application. The pharmaceutical composition is prepared from cyclovirobuxine D, periplocin and swertiamarin. The pharmaceutical composition has the advantages of being stable in mass control, safe, effective, natural, free of toxicity and suitable for being taken for a long term.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for treating atherosclerosis and its application. Background technique [0002] Atherosclerosis is a kind of arteriosclerosis, which mainly occurs in the intima of large and medium arteries, and yellow atheromatous plaques containing cholesterol and fats appear, which are mostly caused by lipid metabolism disorders and neurovascular dysfunction. Often lead to thrombosis, blood supply disorders. The onset of atherosclerosis is more common in men over 40 years old and postmenopausal women. The disease is often accompanied by hypertension, hypercholesterolemia or diabetes. Atherosclerosis is a common disease, frequently-occurring disease, one of the diseases with high mortality and disability, which seriously endangers human life and health. It is common in mental workers and is also one of the main causes of death in the elderly. . [0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61K31/57A61P3/06A61P9/10
CPCA61K31/7048A61K31/57
Inventor 路军秀荆云马丽娟张崇赵繁荣朱茉莉牛秉轩牛慧芳潘国聘李鹏万光瑞
Owner XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap